- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00587639
An Evaluation of Safety and Feasibility Using Repetitive Transcranial Magnetic Stimulation (rTMS) in Adolescents With Depression
March 8, 2012 updated by: Mayo Clinic
An Evaluation of Safety and Feasibility Using rTMS in Adolescents With Depression
The objective of this investigation is to examine the safety and feasibility of a series of repetitive transcranial magnetic stimulation (rTMS) treatments (10 Hertz [Hz]; Left Dorsolateral Prefrontal Cortex), with a Neuronetics Model 2100 Therapy System as adjuvant treatment for depression in adolescent subjects.
Study Overview
Detailed Description
High frequency rTMS applied to the left dorsolateral prefrontal cortex (L-DLPFC) has been shown to have an antidepressant effect.
Initial studies comparing electroconvulsive therapy (ECT) and rTMS suggest that rTMS has been as effective as ECT in treating non-psychotic depression.
Given the high degree of ongoing dysfunction in depressed adolescents despite optimization of treatment with antidepressant medications, new concerns regarding suicidal thoughts and behaviors in adolescents treated with antidepressant medications, and the more interventional nature of ECT, the use of rTMS as adjuvant therapy may be of significant clinical benefit.
Thus far, research using rTMS to treat depression in adolescents has been limited.
The primary aim of this study is to examine the safety and feasibility of using 10 Hz rTMS applied to the left dorsolateral prefrontal cortex (L-DLPFC) as adjuvant treatment for depression in adolescents.
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
13 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) diagnosis of unipolar major depression without psychosis.
- Current or past history of lack of response to at least two adequate antidepressant trials selective serotonin re-uptake inhibitors (SSRI) operationally defined using the Antidepressant Treatment History Form (ATHF)
- Children's Depression Rating Scale-Revised (CDRS-R) score of 40 or higher at baseline
- At least six weeks of ongoing SSRI therapy at a stable dose.
SSRI Medications will include:
- Citalopram (Celexa, Cipramil, Emocal, Sepram)
- Escitalopram oxalate (Lexapro, Cipralex, Esertia)
- Fluoxetine (Prozac, Fontex, Seromex, Seronil, Sarafem, Fluctin (EUR))
- Fluvoxamine maleate (Luvox, Faverin)
- Paroxetine (Paxil, Seroxat, Aropax, Deroxat)
- Sertraline (Zoloft, Lustral, Serlain)
- Age 13-18 years.
- Outpatient, inpatient, or partial hospitalization patients.
- Capable of providing informed assent/consent (in addition to parent/guardian consent).
Exclusion Criteria:
- Current Diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, mental retardation, pervasive developmental disorder, somatoform disorder, dissociative disorder, posttraumatic stress disorder, obsessive-compulsive disorder, eating disorders, antecedents of autism, and all personality disorders.
- Active substance dependence (except nicotine) in the past 12 months.
- Subjects with a history of head trauma, unprovoked seizure history, seizure disorder, or family history of treatment resistant epilepsy.
- Suspected pregnancy or pregnancy as confirmed by a urine pregnancy test at screening.
- History of failure to respond to ECT.
- Metal in the head (except in the mouth), implanted medication pump, cardiac pacemaker.
- Prior brain surgery.
- Risk for increased intracranial pressure such as brain tumor.
- Unable to obtain motor threshold in the subject or motor threshold too high, such that 120% MT cannot be obtained (i.e. >84% of device output).
- Significant change or increase in antidepressant medications within the last six weeks.
- Change in psychiatrist, psychologist, or therapist within the last four weeks.
- Suicide attempt within the past three months.
- Any suicide attempt or suicidal intent during the study will terminate involvement in this study.
- Subjects currently on stimulant, antipsychotic, atypical antidepressant or tricyclic antidepressant medications.
- Unstable medical or neurological conditions that may include hematological, infectious (such as Human immunodeficiency virus [HIV] positive patients) metabolic, or cardiovascular conditions that may preclude safe participation in trial.
- Subjects undergoing anticoagulant, immune suppressive and 1 or chemotherapy, or those who received any of these therapies </=3 months before enrollment in the study
- Subjects with intra-cardiac lines
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: rTMS Treatment
All subjects will have active rTMS treatment (10Hz, L-DLPFC - 3,000 Stimulations/treatment)
|
Active rTMS treatment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Cognitive Status as Measured by the Children's Auditory Verbal Learning Test 2 (CAVLT-2)
Time Frame: Pre-treatment (baseline visit) and post treatment (approximately 6-8 weeks after baseline visit)
|
The Children's Auditory Verbal Learning Test 2 (CAVLT-2) is a neuropsychological test that measures auditory verbal learning and memory.
This test is designed for ages 6.6-17.11
years.
Scores are reported as normalized standard scores.
The minimum standard score is 60 and the maximum 140; a higher score indicates a better performance.
|
Pre-treatment (baseline visit) and post treatment (approximately 6-8 weeks after baseline visit)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Level of Depression at Visit 30, as Measured by the Children's Depression Rating Scale, Revised (CDRS-R)
Time Frame: At study visit 30
|
The Children's Depression Rating Scale, Revised (CDRS-R) is a validated, 17-item, clinician rating tool to assess severity of depression.
Parents provide input into 14 of the items.
Scores range from 0 to 60, with the following scale: not depressed (<20), borderline depressive symptoms (20-29), mild depression (30-39), moderate depression (40-59), severe depression (>/=60).
|
At study visit 30
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Shirlene M. Sampson, M.D., Mayo Clinic
- Principal Investigator: Christopher A. Wall, M.D., Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Wall CA, Croarkin PE, Sim LA, Husain MM, Janicak PG, Kozel FA, Emslie GJ, Dowd SM, Sampson SM. Adjunctive use of repetitive transcranial magnetic stimulation in depressed adolescents: a prospective, open pilot study. J Clin Psychiatry. 2011 Sep;72(9):1263-9. doi: 10.4088/JCP.11m07003.
- Sonmez AI, Kucuker MU, Lewis CP, Kolla BP, Doruk Camsari D, Vande Voort JL, Schak KM, Kung S, Croarkin PE. Improvement in hypersomnia with high frequency repetitive transcranial magnetic stimulation in depressed adolescents: Preliminary evidence from an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2020 Mar 8;97:109763. doi: 10.1016/j.pnpbp.2019.109763. Epub 2019 Oct 18.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2007
Primary Completion (Actual)
October 1, 2009
Study Completion (Actual)
October 1, 2009
Study Registration Dates
First Submitted
December 21, 2007
First Submitted That Met QC Criteria
January 4, 2008
First Posted (Estimate)
January 7, 2008
Study Record Updates
Last Update Posted (Estimate)
March 12, 2012
Last Update Submitted That Met QC Criteria
March 8, 2012
Last Verified
March 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 07-000495
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Lawson Health Research InstituteTerminated
Clinical Trials on rTMS Treatment
-
Changping LaboratoryRecruitingMajor Depressive Disorder | Treatment Resistant DepressionChina
-
Changping LaboratoryWest China Hospital; The Second Affiliated Hospital of Xinxiang Medical University and other collaboratorsRecruitingMajor Depressive Disorder | Treatment Resistant DepressionChina
-
Changping LaboratoryRecruitingObsessive-Compulsive Disorder | OCDChina
-
Changping LaboratoryNot yet recruitingObsessive-Compulsive Disorder | OCD
-
University of ManitobaUnknownAlzheimer's DiseaseCanada, Australia
-
Sunnybrook Health Sciences CentreRecruiting
-
Stanford UniversityNational Institute of Mental Health (NIMH); The Dana FoundationCompleted
-
Ospedale Regionale di LuganoRecruitingMild Cognitive ImpairmentSwitzerland
-
Zhujiang HospitalUnknownPost-stroke DepressionChina
-
Wave NeuroscienceTexas A&M University; GilpinPhillips BIOMED, LLC; Peachtree BioResearch SolutionsRecruitingTraumatic Brain Injury | PostTraumatic Stress Disorder | Postconcussive SymptomsUnited States